Podcasts Science ACC Conversations The Cardiovascular Risk of COX-2 Inhibitors and Other NSAIDs: Reviewing the FDA Advisory Panel Methods, Data and Conclusions

The Cardiovascular Risk of COX-2 Inhibitors and Other NSAIDs: Reviewing the FDA Advisory Panel Methods, Data and Conclusions

Published: Aug. 14, 2006, 5 p.m.

b'The Cardiovascular Risk of COX-2 Inhibitors and Other NSAIDs: Reviewing the FDA Advisory Panel Methods, Data and Conclusions'